Ongwae H Zachariah1, Mwamburi A Lizzy2, Kakai Rose3, Mutuku M Angela4. 1. Department of Health Services, University of Eldoret, P.O. Box 1125, Eldoret, 30100, Kenya. 2. Department of Biological Sciences, University of Eldoret, P.O. Box 1125, Eldoret, 30100, Kenya. lizzymwamburi@hotmail.com. 3. School of Public Health and Community Development, Maseno University, Private Bag, Maseno, Kenya. 4. Department of Biological Sciences, Moi University, P.O. Box 3900, Eldoret, 30100, Kenya.
Abstract
BACKGROUND: Diarrhoea is a common cause of mortality and morbidity in children under five years old. In Kenya, it has a 21% case fatality with Enteropathogenic E. coli, Campylobacter jejuni, Shigella spp. and Salmonella spp. accounting for 50-60% of the cases. Sulphonamides, tetracycline, ampicillin and trimethoprim/sulfamethoxazole are typically used in the treatment of diarrhoeal diseases but have become ineffective in the face of emerging antimicrobial resistance. The objective of this study was to evaluate the prevalence and antimicrobial susceptibility of Campylobacter jejuni and Shigella species in children under five years of age presenting with diarrhoea at Kapsabet County Referral Hospital in Kenya. METHODS: Faecal samples were collected from 139 children admitted with diarrhoea. Each sample was examined macroscopically for colour, texture, and presence of extraneous material. The samples were then cultured for bacterial growth. Observed bacterial growth was isolated and identified by a series of biochemical tests. Resistance patterns were also evaluated using the Kirby - Bauer Disk diffusion method. The chi - square test and Pearson Correlation Coefficient were used to establish statistical significance. RESULTS: Approximately 33.1% of the total faecal samples tested were positive for enteric pathogens. Shigella spp. demonstrated resistance to erythromycin (91.7%), doxycyclin (83.3%), ampicillin (82.1%), cotrimoxazole (73.1%), minocycline (66.7%) and cefuroxime (54.2%). Campylobacter jejuni also exhibited resistance to erythromycin (87.5%), doxycyclin (75%), ampicillin (73.7%), cotrimoxazole (73.3%) and minocycline (68.8%). CONCLUSIONS: The resistance patterns of Shigella spp. and Campylobacter jejuni reported in this study necessitates the need for a comprehensive multiregional investigation to evaluate the geographical prevalence and antimicrobial resistance distributions of these microorganisms. These findings also support the need for the discovery and development of effective therapeutic alternatives. TRIAL REGISTRATION: Retrospectively registered. Certificate No. 00762.
BACKGROUND:Diarrhoea is a common cause of mortality and morbidity in children under five years old. In Kenya, it has a 21% case fatality with Enteropathogenic E. coli, Campylobacter jejuni, Shigella spp. and Salmonella spp. accounting for 50-60% of the cases. Sulphonamides, tetracycline, ampicillin and trimethoprim/sulfamethoxazole are typically used in the treatment of diarrhoeal diseases but have become ineffective in the face of emerging antimicrobial resistance. The objective of this study was to evaluate the prevalence and antimicrobial susceptibility of Campylobacter jejuni and Shigella species in children under five years of age presenting with diarrhoea at Kapsabet County Referral Hospital in Kenya. METHODS: Faecal samples were collected from 139 children admitted with diarrhoea. Each sample was examined macroscopically for colour, texture, and presence of extraneous material. The samples were then cultured for bacterial growth. Observed bacterial growth was isolated and identified by a series of biochemical tests. Resistance patterns were also evaluated using the Kirby - Bauer Disk diffusion method. The chi - square test and Pearson Correlation Coefficient were used to establish statistical significance. RESULTS: Approximately 33.1% of the total faecal samples tested were positive for enteric pathogens. Shigella spp. demonstrated resistance to erythromycin (91.7%), doxycyclin (83.3%), ampicillin (82.1%), cotrimoxazole (73.1%), minocycline (66.7%) and cefuroxime (54.2%). Campylobacter jejuni also exhibited resistance to erythromycin (87.5%), doxycyclin (75%), ampicillin (73.7%), cotrimoxazole (73.3%) and minocycline (68.8%). CONCLUSIONS: The resistance patterns of Shigella spp. and Campylobacter jejuni reported in this study necessitates the need for a comprehensive multiregional investigation to evaluate the geographical prevalence and antimicrobial resistance distributions of these microorganisms. These findings also support the need for the discovery and development of effective therapeutic alternatives. TRIAL REGISTRATION: Retrospectively registered. Certificate No. 00762.
Authors: John T Brooks; John Benjamin Ochieng; Lata Kumar; George Okoth; Roger L Shapiro; Joy G Wells; Michele Bird; Cheryl Bopp; Wairimu Chege; Mark E Beatty; Tom Chiller; John M Vulule; Eric Mintz; Laurence Slutsker Journal: Clin Infect Dis Date: 2006-07-11 Impact factor: 9.079
Authors: John E Moore; Mary D Barton; Iain S Blair; Deborah Corcoran; James S G Dooley; Séamus Fanning; Isabelle Kempf; Albert J Lastovica; Colm J Lowery; Motoo Matsuda; David A McDowell; Ann McMahon; B Cherie Millar; Juluri R Rao; Paul J Rooney; Bruce S Seal; William J Snelling; Ola Tolba Journal: Microbes Infect Date: 2006-03-31 Impact factor: 2.700
Authors: Karen L Kotloff; James P Nataro; William C Blackwelder; Dilruba Nasrin; Tamer H Farag; Sandra Panchalingam; Yukun Wu; Samba O Sow; Dipika Sur; Robert F Breiman; Abu Sg Faruque; Anita Km Zaidi; Debasish Saha; Pedro L Alonso; Boubou Tamboura; Doh Sanogo; Uma Onwuchekwa; Byomkesh Manna; Thandavarayan Ramamurthy; Suman Kanungo; John B Ochieng; Richard Omore; Joseph O Oundo; Anowar Hossain; Sumon K Das; Shahnawaz Ahmed; Shahida Qureshi; Farheen Quadri; Richard A Adegbola; Martin Antonio; M Jahangir Hossain; Adebayo Akinsola; Inacio Mandomando; Tacilta Nhampossa; Sozinho Acácio; Kousick Biswas; Ciara E O'Reilly; Eric D Mintz; Lynette Y Berkeley; Khitam Muhsen; Halvor Sommerfelt; Roy M Robins-Browne; Myron M Levine Journal: Lancet Date: 2013-05-14 Impact factor: 79.321
Authors: Ciara E O'Reilly; Peter Jaron; Benjamin Ochieng; Amek Nyaguara; Jacqueline E Tate; Michele B Parsons; Cheryl A Bopp; Kara A Williams; Jan Vinjé; Elizabeth Blanton; Kathleen A Wannemuehler; John Vulule; Kayla F Laserson; Robert F Breiman; Daniel R Feikin; Marc-Alain Widdowson; Eric Mintz Journal: PLoS Med Date: 2012-07-03 Impact factor: 11.069
Authors: Iruka N Okeke; Oladiipo A Aboderin; Denis K Byarugaba; Kayode K Ojo; Japheth A Opintan Journal: Emerg Infect Dis Date: 2007-11 Impact factor: 6.883